Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports

The U.S. Supreme Court rebuffed a bid by Bristol-Myers’ (BMY) Juno Therapeutics to reinstate a $1.2B award it won in its patent fight with Gilead Sciences’ (GILD) subsidiary Kite Pharma over the lymphoma drug Yescarta, reported Reuters’ Blake Brittain and Andrew Chung. A jury awarded the plaintiffs $778M in damages, which a judge later increased to $1.2B, but the U.S. Court of Appeals for the Federal Circuit threw out the award last year, the report noted. Reference Link